TPG Growth, Steadview Capital, Fidelity, and Hero Group chairman Sunil Kant
Munjal are some of the investors in Nykaa. The company has appointed investment banks such as Kotak Mahindra Capital, Citibank, ICICI Securities, Morgan Stanley, and Bank of America to manage its public issue.
On July 16, the company changed its status from a private company to public by changing the name from FSN e-commerce Ventures Private Limited to FSN e-commerce Ventures Limited.
Nykaa would be the fourth startup to file its DRHP after Zomato, Paytm, and MobiKwik Systems. Paytm has filed DRHP for an IPO to raise Rs 16,600 crore and Mobikwik has filed for a Rs 1,900-crore IPO this month.
Updated:
Developed with DRL, it reduces oxygen-dependence in patients
Share Article
AAA
Defence Minister Rajnath Singh hands over the first batch of 2-DG anti Covid drug to the Union Health Minister Harsh Vardhan, in New Delhi on May 17, 2021. Photo: Twitter/@rajnathsingh
Developed with DRL, it reduces oxygen-dependence in patients
The first batch of the adjunct COVID therapy drug, 2-deoxy-D-glucose (2-DG) developed by the Defence Research and Development Organisation (DRDO) along with Dr Reddy’s Laboratories (DRL), Hyderabad was on Monday released for emergency use. Defence Minister Rajnath Singh formally handed over the drug to Health Minister Dr Harsh Vardhan.
“One box each of the sachets of the drug were handed over to Dr. Randeep Guleria, Director All India Institute of Medical Sciences (AIIMS) and Lt. Gen. Sunil Kant of Armed Forces Medical Services (AFMS). More will be handed over to different hospitals across the country for emergency use,” a Defence M